Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...
Exelixis stock holds firm with $41 target from JMP Securities
JMP Securities maintained a Market Outperform rating and a $41.00 price target for Exelixis (NASDAQ:EXEL) shares, aligning with the broader analyst consensus as five analysts have recently revised ...
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.
MedCity News10d
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...
FierceBiotech12d
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...
Metsera Announces Pricing of Initial Public Offering
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...
pharmaphorum11d
Two more biotechs, Metsera and Maze, cross IPO finish line
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...
Metsera, Inc IPOs Tomorrow, Here's What You Need To Know
Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...
Nasdaq12d
Metsera, Inc. Prices Initial Public Offering at $18.00 per Share, Aiming for $275 Million Gross Proceeds
Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering ...
Seeking Alpha11d
Metsera sees stock rally 54% following $275M IPO
Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...
BioPharma Dive12d
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...